Quantcast

Latest Ibritumomab tiuxetan Stories

2008-12-08 00:30:00

SEATTLE, Dec. 8 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that extended follow-up data for the Zevalin(R) ([90Y]-ibritumomab tiuxetan) First-line Indolent (FIT) study presented at the American Society of Hematology (ASH) 50th Annual Meeting by Morschhauser, et al demonstrated the continued improvement in progression-free survival (PFS) following Zevalin consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who...

2008-12-04 00:30:00

SEATTLE, Dec. 4 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today announced presentations or posters of interest related to Zevalin(R) (ibritumomab tiuxetan) to be presented at the 50th Annual Meeting of the American Society of Hematology (ASH), December 5-9, 2008 in San Francisco. In addition, James Bianco, M.D., CEO of Cell Therapeutics will participate in a panel hosted by Biotechnology Industry Organization and Gerson Lehrman Group(R), "Gerson...

2008-12-01 00:30:00

SEATTLE, Dec. 1 /PRNewswire-FirstCall/ -- On Monday, December 1, 2008, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, Cell Therapeutics, Inc.'s (CTI) (Nasdaq and MTA: CTIC) management team will host a conference call to discuss the agreement with Spectrum Pharmaceuticals of Irvine, California to jointly market and develop Zevalin(R). The call will be webcast with slides, and the slides are also available for review on CTI's website,...

2008-12-01 00:30:00

SEATTLE, Dec. 1 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and review, and has granted priority review status for, the supplemental Biologics License Application (sBLA) for use of Zevalin(R) ([90Y]-ibritumomab tiuxetan) as consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy. Priority review is...

2008-11-13 03:00:16

Cell Therapeutics, a biopharmaceutical company, has achieved the primary efficacy endpoint of its Phase III Extend trial of pixantrone for patients with advanced, relapsed aggressive non-Hodgkin's lymphoma based on a preliminary intent to treat efficacy analysis. The Extend clinical trial is a Phase III single-agent trial of pixantrone for patients with relapsed, aggressive non-Hodgkin's lymphoma who received two or more prior therapies and who were sensitive to treatment with...

2008-11-11 03:00:09

SEATTLE, Nov. 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it achieved the primary efficacy endpoint of its phase III EXTEND (PIX301) trial of pixantrone (BBR2778) for patients with advanced, relapsed aggressive non-Hodgkin's lymphoma (NHL) based on a preliminary intent to treat efficacy analysis. Patients randomized to treatment with pixantrone achieved a high rate of confirmed and unconfirmed complete remissions compared to...

2008-11-04 06:00:10

Having gained approval as a treatment for chronic lymphocytic leukemia earlier this year, the FDA has now extended Treanda's use to indolent B-cell non-Hodgkin's lymphoma. Although Treanda's total sales are set to increase following its approval in this more significant commercial market, Cephalon's drug is likely to face competition from pipeline drugs currently in late-stage development. Approval of Treanda for non-Hodgkin's lymphoma (NHL) followed the results of a Phase III trial in...

2008-11-03 09:00:40

Cell Therapeutics, a biopharmaceutical company, has closed the data set for preliminary analysis of the primary endpoint in the Phase III Extend trial of pixantrone for patients with relapsed diffuse large B cell non-Hodgkin's lymphoma. It has also notified Novartis that the data set has been closed. The primary endpoint for the study is the complete remission (CR) and unconfirmed complete remission (uCR) rate in patients receiving either pixantrone or another single agent chemotherapeutic...

2008-11-03 09:00:39

Cephalon, a biopharmaceutical company, has announced that the FDA has approved Treanda for injection for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. According to the company, the data supporting the FDA approval show that Treanda is effective, has a tolerable side effect profile in patients with indolent non-Hodgkin's lymphoma (NHL) and that treatment...

2008-10-27 09:00:11

Genentech, Inc. (NYSE:DNA) and Biogen Idec, Inc. (Nasdaq:BIIB) announced that Rituxan(R) (rituximab) data including results from Phase II and III studies of Rituxan in patients with moderately-to-severely active rheumatoid arthritis (RA) will be featured in two podium presentations and eight poster presentations at the American College of Rheumatology (ACR) Annual Scientific Meeting in San Francisco this week. Among the studies being presented are a Phase III controlled re-treatment...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.